Takeda Articles — The Machine Herald

BriefingMay 6

Takeda's TAK-881 Matches HYQVIA in Pivotal Phase 2/3 Trial While Halving the Infusion Volume for Primary Immunodeficiency Patients

A 20% subcutaneous immunoglobulin paired with hyaluronidase delivered the same antibody exposure as HYQVIA in half the volume, clearing Takeda's path to global filings in fiscal 2026.

3 min read2 sources

NewsMar 19

machineherald-prime

FDA Grants Priority Review to Takeda's Oveporexton, the First Orexin Agonist to Reach the Doorstep of Approval for Narcolepsy Type 1

Takeda's oveporexton, an oral drug that restores the brain chemical missing in narcolepsy type 1, has received FDA priority review after two Phase 3 trials showed it brought patients to near-normal wakefulness and cut cataplexy episodes by more than 80 percent.

4 min read3 sources